Sign in or create an account to add this stock to your watchlist.
About GW Pharmaceuticals (NASDAQ:GWPH)
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. Its lead product is Epidiolex, an oral medicine which is in Phase III clinical development for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates, which are in Phase I and II clinical development for the treatment of glioma, neonatal hypoxic-ischemic encephalopathy, adult epilepsy, and schizophrenia. Further, the company has license and development agreements with Otsuka Pharmaceutical Co. Ltd.; Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GWPH
CUSIPN/A
Phone44-12-2326-6800
Debt
Debt-to-Equity Ratio0.01
Current Ratio11.32
Quick Ratio11.22
Price-To-Earnings
Trailing P/E Ratio-23.18
Forward P/E Ratio-16.57
P/E GrowthN/A
Sales & Book Value
Annual Sales$11 million
Price / Sales406.70
Cash FlowN/A
Price / CashN/A
Book Value$20.21 per share
Price / Book7.97
Profitability
EPS (Most Recent Fiscal Year)($6.95)
Net Income$-166,900,000.00
Net Margins-1,516.94%
Return on Equity-53.37%
Return on Assets-46.73%
Miscellaneous
Employees583
Outstanding Shares27,770,000
GW Pharmaceuticals (NASDAQ:GWPH) Frequently Asked Questions
What is GW Pharmaceuticals' stock symbol?
GW Pharmaceuticals trades on the NASDAQ under the ticker symbol "GWPH."
How were GW Pharmaceuticals' earnings last quarter?
GW Pharmaceuticals (NASDAQ:GWPH) announced its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($3.12) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($2.22) by $0.90. The biopharmaceutical company had revenue of $3.35 million for the quarter, compared to analyst estimates of $2.04 million. GW Pharmaceuticals had a negative return on equity of 53.37% and a negative net margin of 1,516.94%. GW Pharmaceuticals's revenue for the quarter was up 112.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.70) earnings per share. View GW Pharmaceuticals' Earnings History.
When is GW Pharmaceuticals' next earnings date?
What price target have analysts set for GWPH?
7 Wall Street analysts have issued 12 month price targets for GW Pharmaceuticals' shares. Their forecasts range from $61.00 to $205.00. On average, they expect GW Pharmaceuticals' share price to reach $152.1429 in the next year. View Analyst Ratings for GW Pharmaceuticals.
What are Wall Street analysts saying about GW Pharmaceuticals stock?
Here are some recent quotes from research analysts about GW Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. " (5/11/2018)
- 2. Cantor Fitzgerald analysts commented, "Europe Follows Suit. Following acceptance of the Epidiolex application by the FDA in December, GW announced European acceptance of the application today. In the U.S., the review is expedited, with an advisory panel in 2Q18 and a PDUFA date on June, 27 2018. The company expects a European decision by 1Q19." (2/5/2018)
Who are some of GW Pharmaceuticals' key competitors?
Some companies that are related to GW Pharmaceuticals include BioMarin Pharmaceutical (BMRN), Grifols (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Nektar Therapeutics (NKTR), Merck Group (MKGAF), Genmab (GNMSF), Perrigo (PRGO), BeiGene (BGNE), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS) and Sarepta Therapeutics (SRPT).
Who are GW Pharmaceuticals' key executives?
GW Pharmaceuticals' management team includes the folowing people:
- Dr. Geoffrey W. Guy BSc, LMSSA, Dip Pharm Med, MB BS, MRCS Eng, LRCP, Founder & Exec. Chairman (Age 64)
- Mr. Justin D. Gover, CEO & Exec. Director (Age 47)
- Mr. Scott M. Giacobello, Chief Financial Officer (Age 48)
- Mr. Christopher John Tovey BSc, Chief Operating Officer (Age 53)
- Mr. Douglas B. Snyder, Chief Legal Officer (Age 54)
Has GW Pharmaceuticals been receiving favorable news coverage?
Press coverage about GWPH stock has been trending somewhat positive on Monday, Accern Sentiment reports. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. GW Pharmaceuticals earned a coverage optimism score of 0.11 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 46.00 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are GW Pharmaceuticals' major shareholders?
GW Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Scopia Capital Management LP (9.78%), BlackRock Inc. (2.79%), Point72 Asset Management L.P. (1.31%), Rock Springs Capital Management LP (1.30%), Victory Capital Management Inc. (1.08%) and Millennium Management LLC (0.86%). View Institutional Ownership Trends for GW Pharmaceuticals.
Which major investors are selling GW Pharmaceuticals stock?
GWPH stock was sold by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, OppenheimerFunds Inc., Franklin Resources Inc., Point72 Asset Management L.P., Hsbc Holdings PLC, AGF Investments Inc., C WorldWide Group Holding A S and Greenleaf Trust. View Insider Buying and Selling for GW Pharmaceuticals.
Which major investors are buying GW Pharmaceuticals stock?
GWPH stock was purchased by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, Millennium Management LLC, Victory Capital Management Inc., UBS Group AG, JPMorgan Chase & Co., Rock Springs Capital Management LP, Alps Advisors Inc. and Wells Fargo & Company MN. View Insider Buying and Selling for GW Pharmaceuticals.
How do I buy shares of GW Pharmaceuticals?
Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GW Pharmaceuticals' stock price today?
One share of GWPH stock can currently be purchased for approximately $161.10.
How big of a company is GW Pharmaceuticals?
GW Pharmaceuticals has a market capitalization of $4.47 billion and generates $11 million in revenue each year. The biopharmaceutical company earns $-166,900,000.00 in net income (profit) each year or ($6.95) on an earnings per share basis. GW Pharmaceuticals employs 583 workers across the globe.
How can I contact GW Pharmaceuticals?
GW Pharmaceuticals' mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]
MarketBeat Community Rating for GW Pharmaceuticals (GWPH)
MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals and other stocks. Vote "Outperform" if you believe GWPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GWPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
GW Pharmaceuticals (NASDAQ:GWPH) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for GW Pharmaceuticals in the last 12 months. Their average twelve-month price target is $152.1429, suggesting that the stock has a possible downside of 5.56%. The high price target for GWPH is $205.00 and the low price target for GWPH is $61.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.86 | 2.86 | 2.86 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $152.1429 | $152.1429 | $150.2857 | $146.25 |
| Price Target Upside: | 5.56% downside | 14.06% upside | 13.57% upside | 27.43% upside |
GW Pharmaceuticals (NASDAQ:GWPH) Consensus Price Target History
GW Pharmaceuticals (NASDAQ:GWPH) Analyst Ratings History
Show:
(Data available from 5/28/2016 forward)
GW Pharmaceuticals (NASDAQ:GWPH) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
GW Pharmaceuticals (NASDAQ GWPH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 71.69%
GW Pharmaceuticals (NASDAQ GWPH) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
GW Pharmaceuticals (NASDAQ GWPH) News Headlines
| Source: |
|
GW Pharmaceuticals (NASDAQ:GWPH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
GW Pharmaceuticals (NASDAQ:GWPH) Income Statement, Balance Sheet and Cash Flow Statement
GW Pharmaceuticals (NASDAQ GWPH) Stock Chart for Monday, May, 28, 2018
Loading chart…
